• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CC5

CLEVER CULTURE SYSTEMS LIMITED - News & Media

5.56% ! 1.7¢
Market Cap $30.01M  !
Healthcare Biotechnology
Add to My Watchlist

Clever Culture Systems Limited, formerly LBT Innovations Limited, is an Australia-based... Clever Culture Systems Limited, formerly LBT Innovations Limited, is an Australia-based company that provides intelligent automation solutions to microbiology laboratories. The Company has developed a technology, the Automated Plate Assessment System (APAS Independence), using artificial intelligence (AI) and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology is a United States FDA-cleared AI technology for automated culture plate reading. The product is being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is the exclusive distributor of the APAS Independence to clinical customers in the United States and selected countries in Europe.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

AstraZeneca orders 4 more microbiological scanners from Clever Culture Systems for $3M

Clever Culture Systems (ASX:CC5) has confirmed its received an order for 4 of its 'APAS' systems from pharma giant AstraZeneca.

05 Dec 2024 10:33 (AEDT)

LBT inks $4.1M deal with AstraZeneca for AI platform technology

LBT Innovations Ltd has seen its share price rise more than 33% on news of the deal with the multinational pharmaceutical company.

07 Aug 2024 12:16 (AEST)

LBT Innovations (ASX:LBT) partners with AstraZeneca for APAS Pharma development

LBT Innovations (ASX:LBT) has been engaged by AstraZeneca to undertake a full product development project for its APAS Pharma product.

09 Jan 2023 14:12 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.7¢ 		Change
-0.001(5.56%) 		Mkt cap ! $30.01M
Open High Low Value Volume
1.8¢ 1.8¢ 1.7¢ $7.147K 406.5K

Buyers (Bids)

No. Vol. Price($)
5 666706 1.7¢
 

Sellers (Offers)

Price($) Vol. No.
1.8¢ 610640 2
View Market Depth
Last trade - 14.23pm 13/06/2025 (20 minute delay) ?
CC5 (ASX) Chart

Top Stories

Resolution's dual-listing to 'expedite growth' – and sets stage for NASDAQ foray

Resolution Minerals (ASX:RML) is on the verge of listing on the OTCQB @ oft called the @Venture Market” over in the States @ as it looks to @expedite growth” and @unlock value” through the bold U.S. index expansion.Listen to the Ho...
Iberian expansion: Megado turns to Europe with Spanish copper mines Megado Minerals has added the Iberian Copper Project in Spain to its expanding collection after buying an 80% interest in Iberian Copper.
Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing) Welcome to this week’s HotCopperWire, our market watch podcast!Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through all the week’s biggest news headlines @ and what they mean for Aussie investors.In this Week ...
HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back Good Afternoon and welcome to HotCopper Highlights for Week 24 of the year, I’m Jon Davidson. In this segment we look at some of the...
Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing By and large, I don't think I'd be without peers when I said the biggest thing that happened this week was on energy markets.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.